SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION

BACKGROUND: Brain metastases (BMs) occur in 20–40% of patients with METex14 skipping NSCLC. Tepotinib, a highly selective MET inhibitor, demonstrated an objective response rate (ORR) of 49.1% and median duration of response (mDOR) of 13.8 months, in METex14 skipping NSCLC patients in the Phase II VI...

Descripción completa

Detalles Bibliográficos
Autores principales: Leighl, Natasha, Bestvina, Christine, Patel, Jyoti, Le, Xiuning, Veillon, Remi, Anderson, Ian, Demedts, Ingel, Garassino, Marina Chiara, Mazières, Julien, Morise, Masahiro, Smit, Egbert, Eggleton, S Peter, O’Brate, Aurora, Otto, Gordon, Bruns, Rolf, Schumacher, Karl Maria, Paik, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354189/
http://dx.doi.org/10.1093/noajnl/vdac078.085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354189/
http://dx.doi.org/10.1093/noajnl/vdac078.085

Ejemplares similares